Critical Contrast: Omni Bio Pharmaceutical (OTCMKTS:OMBP) & Vericel (OTCMKTS:VCEL)
Omni Bio Pharmaceutical (OTCMKTS:OMBP) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
This table compares Omni Bio Pharmaceutical and Vericel’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Omni Bio Pharmaceutical||N/A||N/A||N/A|
This is a breakdown of recent recommendations and price targets for Omni Bio Pharmaceutical and Vericel, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Omni Bio Pharmaceutical||0||0||0||0||N/A|
Vericel has a consensus target price of $24.25, indicating a potential upside of 47.06%. Given Vericel’s higher probable upside, analysts plainly believe Vericel is more favorable than Omni Bio Pharmaceutical.
Institutional & Insider Ownership
88.5% of Vericel shares are held by institutional investors. 4.3% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Omni Bio Pharmaceutical has a beta of -22.08, suggesting that its stock price is 2,308% less volatile than the S&P 500. Comparatively, Vericel has a beta of 2.97, suggesting that its stock price is 197% more volatile than the S&P 500.
Valuation and Earnings
This table compares Omni Bio Pharmaceutical and Vericel’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Omni Bio Pharmaceutical||N/A||N/A||N/A||N/A||N/A|
|Vericel||$117.85 million||6.31||-$9.66 million||$0.18||91.61|
Omni Bio Pharmaceutical has higher earnings, but lower revenue than Vericel.
Vericel beats Omni Bio Pharmaceutical on 8 of the 9 factors compared between the two stocks.
Omni Bio Pharmaceutical Company Profile
Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Omni Bio Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omni Bio Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.